| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6197341 | VALEANT PHARMS INTL | Formulations of balsalazide and its derivatives |
Mar, 2018
(6 years ago) | |
| US9192616 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(2 years from now) | |
| US8497256 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males |
Jun, 2031
(7 years from now) | |
Giazo is owned by Valeant Pharms Intl.
Giazo contains Balsalazide Disodium.
Giazo has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Giazo are:
- US6197341
Giazo was authorised for market use on 03 February, 2012.
Giazo is available in tablet;oral dosage forms.
Giazo can be used as treatment of mildly to moderately active ulcerative colitis in male patients.
The generics of Giazo are possible to be released after 23 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 03, 2015 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 03 February, 2012
Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients
Dosage: TABLET;ORAL
GIAZO family patents
